OMass Therapeutics to Present at Upcoming Conferences

Published

March 3, 2022

OMass Therapeutics to Present at Upcoming Conferences

Oxford, United Kingdom – 21 February 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to confirm that it will be presenting at a number of upcoming banking, business and scientific conferences, as detailed below.

Rosamond Deegan, CEO of OMass of OMass said: “As we develop our unique drug discovery platform, OdyssION™, and progress our pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bound proteins and GPCRs, we are delighted to have the opportunity to share our progress with financial, pharma, biotech and scientific audiences.”

If you would like to meet with any of the OMass team during these events or at any other time, please contact miguel.silva@omass.com .

-ENDS-

For further information, please contact:

OMass Therapeutics Consilium Strategic Communications
Rosamond Deegan, Chief Executive Officer

Phone: +44 (0)1235 527589

Email: ros.deegan@omass.com

 

Sue Charles / Chris Gardner / Kumail Waljee

Phone: +44 (0)20 3709 5700

Email: omass@consilium-comms.com

 

About OMass Therapeutics

OMass Therapeutics is a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes. The Company’s unique technology platform, OdyssION™, comprises novel biochemistry techniques, next generation native mass spectrometry and custom chemistry. This allows OMass to interrogate not just the target but how it interacts with its native ecosystem, separate from the confounding complexity of the cell. The result is cell-system fidelity with cell-free precision. OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bound proteins and GPCRs.

Headquartered in Oxford, UK, OMass is backed by a top-tier investor syndicate, Syncona and Oxford Science Enterprises, having closed a ~$60m Series A funding.

To learn more, please visit www.omass.com. Follow us on LinkedIn and Twitter.

MORERelated News
OMass Therapeutics Appoints Dr Jon Roffey as Vice President, Head of Medicinal Chemistry
Oxford, United Kingdom – 15 July 2022 – OMass Therapeutics (‘OMass’, or ‘the Company’), a biotechnology company that identifies medicines...
OMass Therapeutics Wins the Oxford Science Park Innovation Award at the Oxfordshire Business Awards
Oxford, United Kingdom – 20 June 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against...
OMass Therapeutics Announces its Attendance at Upcoming Conferences and Events
Oxford, United Kingdom – 14 June 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against...